Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accounts Payables (2021 - 2026)

Centessa Pharmaceuticals has reported Accounts Payables over the past 5 years, most recently at $7.6 million for Q4 2025.

  • Quarterly Accounts Payables rose 6.15% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 6.15% year-over-year, with the annual reading at $7.6 million for FY2025, 6.15% up from the prior year.
  • Accounts Payables was $7.6 million for Q4 2025 at Centessa Pharmaceuticals, down from $8.7 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $14.4 million in Q1 2023 and troughed at $5.1 million in Q1 2025.
  • The 5-year median for Accounts Payables is $8.1 million (2021), against an average of $8.8 million.
  • Year-over-year, Accounts Payables surged 114.8% in 2023 and then tumbled 52.01% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $8.1 million in 2021, then skyrocketed by 71.56% to $13.8 million in 2022, then decreased by 14.61% to $11.8 million in 2023, then tumbled by 39.54% to $7.1 million in 2024, then increased by 6.15% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Accounts Payables are $7.6 million (Q4 2025), $8.7 million (Q3 2025), and $5.7 million (Q2 2025).